TIANJIN Zhong Xin Pharmaceutical Group has posted a net profit of 567.8 million yuan for FY2018, up 20 per cent from 473.3 million yuan a year ago, lifted by interest income and gains from associated companies Sino-American Tianjin Smithkline & French Lab and Tianjin Hong Ren Tang Pharmaceutical Co.
Revenue for the full year stood at 6.4 billion yuan, up 12 per cent from 5.7 billion yuan previously, on the back of newly introduced products such as Qingyan Pills, Huoxiang Zhengqi Capsule and Tezacef.A proposed dividend of 2.2 yuan for every 10 shares was declared by the company, compared to 2.0 yuan for every 10 shares in FY2017.The company noted that challenges in the external environment exerted downward pressure on China's economy and triggered changes in the financial market.
It added that it will continue to improve on quality and efficiency through innovative use of its resources.